Skip to main content
. 2021 Jun 11;100(23):e26295. doi: 10.1097/MD.0000000000026295

Figure 3.

Figure 3

A meta-analysis of GLP-1 receptor agonists versus metformin for primary outcomes. (A) BMI = body mass index, (B) MFR = menstrual frequency, (C) TT = serum total testosterone, (D) HOMA-IR = homeostasis model assessment of insulin resistance.